Xilio Therapeutics, Inc.
XLO$42M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM64 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 30, 2026
7wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
vilastobart (XTX101) Phase 2 Results Expected
Mar 30, 2026vilastobart (XTX101)136
Primary completion for vilastobart (XTX101) trial (NCT04896697) in Advanced Solid Tumor
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
XTX202
Advanced Solid Tumor
vilastobart (XTX101)
Advanced Solid Tumor
XTX301
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
XTX202 | Phase 2 | Advanced Solid Tumor | - |
vilastobart (XTX101) | Phase 2 | Advanced Solid Tumor | - |
XTX301 | Phase 2 | Advanced Solid Tumor | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
XLO News